



Production of novel medically relevant radiolanthanides at Paul Scherrer Institute


Dr. Zeynep Talip


PRISMAP Radiolanthanides Workshop, 3 September 2024

Radiopharmaceutical Development Pipeline



**PRISMAP
RADIOLANTHANIDES
WORKSHOP**







How can **personalized dosimetry** be improved to optimize the therapeutic index of TRT?


How can **Auger electron therapy** be integrated into current treatment protocols to improve overall treatment efficacy?

**Availability of
a diverse array of radionuclides**



**Systematic
preclinical studies**





Proper **decay properties** for Nuclear Medicine applications

Analogue coordination chemistry



Clinically approved Lu-177 will shorten the translation period of the other radiolanthanides to the clinics
– **Tb-161** is on the way





Radiolanthanides in Nuclear Medicine






57 La Lanthanum 138.905	58 Ce Cerium 140.116	59 Pr Praseodymium 140.908	60 Nd Neodymium 144.242	61 Pm Promethium 144.913	62 Sm Samarium 150.36	63 Eu Europium 151.964	64 Gd Gadolinium 157.25	65 Tb Terbium 158.925	66 Dy Dysprosium 162.500	67 Ho Holmium 164.930	68 Er Erbium 167.259	69 Tm Thulium 168.934	70 Yb Ytterbium 173.055	71 Lu Lutetium 174.967
---	--------------------------------------	--	---	--	---------------------------------------	--	---	---------------------------------------	--	---------------------------------------	--------------------------------------	---------------------------------------	---	--

Pr 143 13.57 d β^-	Pm 149 53.1 h β^-	Sm 153 46.28 h β^-	Tb 161 6.95 d β^-	Ho 166 26.81 h β^-	Er 169 9.392 d β^-	Yb 175 4.185 d β^-	Lu 177 6.64 d β^-
	Tb 152 17.5 h β^+, EC	Ho 161 2.48 h EC	Er 165 10.36 h EC	Tb 155 5.32 d EC	La 135 19.4 h $\beta^+ EC$	Tm 167 9.25 d EC	
		Tb 149 4.1 h $\beta^+ \alpha$					





Terbium Swiss knife



Auger emitting radiolanthanides



Beta emitting radiolanthanides



Beta emitting radiolanthanides

Er 169 9.392 d β^-	Lu 177 6.64 d β^-	Tb 161 6.95 d β^-	Pr 143 13.57 d β^-	Ho 166 26.82 h β^-
--------------------------------	-------------------------------	-------------------------------	--------------------------------	--------------------------------

Average
 β^- energies:

100 keV

134 keV

154 keV


315 keV

665 keV

Medium
size lesions

Big
size lesions










AE & CE

C. Müller et al., *Eur. J. Nucl. Med. Mol Imaging*, 50, 3181 (2023)

TANDEM Therapy





Production cross section measurements



E. Renaldin et al., *Front. Chem.*, 11, 14 (2023).



Production yield measurements



40 mg $^{168}\text{Er}_2\text{O}_3$ target (^{168}Er : 98.3%)

25 μA , 23 MeV, 8 h irradiation EOB: 1 GBq


5 days cooling 99.50% radionuclidic purity




40 mg $^{171}\text{Yb}_2\text{O}_3$ target (^{171}Yb : 95.5%)

25 μA , 51 MeV, 8 h irradiation EOB: 420 MBq

5 days cooling 99.95% radionuclidic purity




$m_{\text{Dy-164},0} = 650 \mu\text{g}$
 96.8 % enriched
 6 days irradiation





Ho 165 100 σ 3.5 + 60.9 $\sigma_{n,\alpha} < 2E-5$	Ho 166 1132.6 a 26.824 h β^- 0.07 1.3... γ 184, 810 712... σ 10778	
Dy 164 28.260 σ 1610 + 1040	Dy 165 1.257 m 2.334 h Γ 108, e^- β^- 0.9 1.0... γ 515... σ 2000	Dy 166 81.5 h β^- 0.4, 0.5... γ 82, (426...) e^- g

$m_{Dy-164,0} = 650 \mu g$
 96.8 % enriched
 6 days irradiation




Pr 141 100 σ 3.9 + 7.4	Pr 142 14.6 m 19.12 h β^- 2.2... ϵ 1576... τ (4), e^- σ 20	Pr 143 13.57 d β^- 0.9... γ (742) σ 90	Pr 144 7.2 m 17.28 m τ (59), e^- β^- ... β^- 3.0... γ (697) (7186)
Ce 140 88.450 σ 0.51	Ce 141 32.511 d β^- 0.4, 0.6 γ 145 σ 29	Ce 142 11.114 σ 0.96	Ce 143 33.039 h β^- 1.1, 1.5... γ 293, 57, 665 γ 722..., e^- σ 6.0




250 MBq of ^{143}Pr per mg of enriched $^{142}\text{CeO}_2$

- Investigation of different **extraction resins (LN Resins, TK resins, DGA)**



- Investigation of different **cation exchange resins**




- Investigation of different **complexing agents**, alternative to α -HIB

- Radiation damage effects** on the extraction resins




Separation of Radiolanthanides

Gd and Tb separation for ^{161}Tb production
 reactor produced
 $^{160}\text{Gd} (n,\gamma) ^{161}\text{Gd} \rightarrow ^{161}\text{Tb}$



Separation: 1.5 days

Gd and Tb separation for ^{155}Tb production
 cyclotron-produced
 $^{156}\text{Gd} (p,2n) ^{155}\text{Tb}$



Separation: 6 - 7 hours

N. Gracheva et al., *EJNMMI Radiopharmacy and Chemistry*, 159, 109085 (2020).

C. Favaretto et al., *EJNMMI Radiopharmacy and Chemistry*, 6, 37 (2021).



Tm and Er separation

5 μg Er, 5 μg Tm

Loading: 1 mL 0.75 M HNO_3

Eluent: 2 M HNO_3

Column volume: 3 mL column





5 μg Er, 5 μg Tm


Loading: 1 mL 0.25 M HNO_3

Eluent: 0.75 M HNO_3

Column volume: 3 mL column



Effect of target mass on TK212 resins




5 µg Er, 5 µg Tm

Loading: 1 mL 0.25 M HNO₃;

Eluent: 0.75 M HNO₃

Column volume: 3 mL column



20 mg Er, 200 µg Tm

Loading: 1 mL 0.25 M HNO₃;

Eluent: 0.75 M HNO₃

Column volume: 16 mL column

Comparison of cation exchange resins



5 μg Er, 5 μg Tm

Loading: 5 mL water

Eluent: 0.07 M α -HIBA pH 4.5

Column volume: 3 mL column

Sykam




Particle size: 12-22 μM

Dowex

100-200 μM

AGMP50

100-200 μM



PSI-Injector 2 cyclotron


^{167}Tm $^{168}\text{Er}(p,2n)^{167}\text{Tm}$ (1 GBq, 99.5% radionuclidic purity)
 $^{171}\text{Yb}(p,5n)^{167}\text{Lu}$ (420 Mbq, 99.95% radionuclidic purity)

ILL nuclear reactor

32 GBq radionuclidically pure ^{166}Ho per mg of enriched $^{164}\text{Dy}_2\text{O}_3$

250 MBq of radionuclidically pure ^{143}Pr per mg of enriched $^{142}\text{CeO}_2$

Two different lanthanide separation methods were developed, and alternative chemical separation methods for radiolanthanides are in progress.



Acknowledgement



Wir schaffen Wissen – heute für morgen
We create knowledge - today for tomorrow

Prof. Dr. Robert Eichler
Prof. Dr. Roger Schibli

Radionuclide Development group

Dr. Nicholas van der Meulen
Dr. Pascal Grundler
Dr. Chiara Favaretto
Edoardo Renaldin
Ramon Zehnder
Sofia Pasolini
Colin Hillhouse

Radionuclide - Production and Maintenance group

Roger Geissmann
Alexander Sommerhalder
Muhamet Djelili

Nuclide Chemistry group

Prof. Dr. Cristina Müller
Dr. Francesca Borgna
Fan Sozzi

PSI GFA

Dr. Hui Zhang

ILL

Prof. Dr. Ulli Koester

Laboratory of High Energy Physics (Unibe)

Prof. Dr. Saverio Braccini
Gaia Dellepiane

IRA-CHUV


Dr. Frederic Juget
Dr. Youcef Nedjadi
Dr. Teresa Duran
Dr. Claude Bailat

CERN MEDICIS

Dr. Thierry Stora
Dr. Charlotte Duchemin
& MEDICIS team

PSI Hot-Lab

Vitor Rodrigues



Thank You For Your Attention!



PRISMAP
RADIOLANTHANIDES
WORKSHOP